2. GPCR/G Protein Neuronal Signaling Autophagy Apoptosis
  3. 5-HT Receptor Dopamine Receptor mAChR Adrenergic Receptor Autophagy Mitophagy Apoptosis
  4. Olanzapine

Olanzapine (LY170053) is a selective, orally active monoaminergic antagonist with high affinity binding to serotonin H1, 5HT2A/2C, 5HT3, 5HT6 (Ki=7, 4, 11, 57, and 5 nM, respectively), dopamine D1-4 (Ki=11 to 31 nM), muscarinic M1-5 (Ki=1.9-25 nM), and adrenergic α1 receptor (Ki=19 nM). Olanzapine is an atypical antipsychotic.

For research use only. We do not sell to patients.

CAS No. : 132539-06-1

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
50 mg In-stock
100 mg In-stock
250 mg In-stock
500 mg In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 14 publication(s) in Google Scholar

Other Forms of Olanzapine:

Olanzapine Related Antibodies

Top Publications Citing Use of Products

    Olanzapine purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Nov 10;13(1):6796.  [Abstract]

    Relative CHOP-Luc activities of individual tested compounds (Olanzapine) at 20 µM in the presence of Tm/Tg (1 µM) relative to DMSO, 24 hours after exposure.

    Olanzapine purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2021 Aug;42(8):1267-1279.  [Abstract]

    Olanzapine (Ola: 1.0 mg/kg). Serum insulin-metabolizing hormone levels were measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit.

    Olanzapine purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2021 Aug;42(8):1267-1279.  [Abstract]

    Olanzapine (Ola: 1.0 mg/kg). The expression level of GLP-1 protein in small intestinal tissue was detected by Western blot analysis.

    Olanzapine purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2021 Aug;42(8):1267-1279.  [Abstract]

    Olanzapine (Ola: 1.0 mg/kg). GLP-1 immunohistochemical staining was performed on paraffin sections of the small intestine.

    Olanzapine purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2021 Aug;42(8):1267-1279.  [Abstract]

    Olanzapine (Ola: 1.0 mg/kg). The mRNA expression level in liver tissue was detected using real-time quantitative PCR.

    View All 5-HT Receptor Isoform Specific Products:

    View All Isoforms
    5-HT Receptor 5-HT1 Receptor 5-HT2 Receptor 5-HT3 Receptor 5-HT4 Receptor 5-HT5 Receptor 5-HT6 Receptor 5-HT7 Receptor

    View All Dopamine Receptor Isoform Specific Products:

    View All Isoforms
    Dopamine Receptor D1 Receptor D2 Receptor D3 Receptor D4 Receptor D5 Receptor

    View All mAChR Isoform Specific Products:

    View All Isoforms
    mAChR1 mAChR2 mAChR3 mAChR4 mAChR5

    View All Adrenergic Receptor Isoform Specific Products:

    View All Isoforms
    α adrenergic receptor β adrenergic receptor

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Olanzapine (LY170053) is a selective, orally active monoaminergic antagonist with high affinity binding to serotonin H1, 5HT2A/2C, 5HT3, 5HT6 (Ki=7, 4, 11, 57, and 5 nM, respectively), dopamine D1-4 (Ki=11 to 31 nM), muscarinic M1-5 (Ki=1.9-25 nM), and adrenergic α1 receptor (Ki=19 nM). Olanzapine is an atypical antipsychotic[1][2].

    IC50 & Target[1]

    5-HT2A Receptor

    4 nM (Ki)

    5-HT2A Receptor

     

    5-HT6 Receptor

     

    5-HT1 Receptor

    7 nM (Ki)

    5-HT6 Receptor

    5 nM (Ki)

    5-HT2C Receptor

    11 nM (Ki)

    5-HT3 Receptor

    57 nM (Ki)

    Adrenergic α1 Receptor

    19 nM (Ki)

    Muscarinic M1-5 Receptor

    1.9-25 nM (Ki)

    Dopamine Receptor

     

    Mitophagy

     

    Apoptosis

     

    Cellular Effect
    Cell Line Type Value Description References
    CHO IC50
    0.173 μM
    Compound: olanzapine
    Inhibitory concentration against human Dopamine receptor D4.2 in CHO cells
    Inhibitory concentration against human Dopamine receptor D4.2 in CHO cells
    		[PMID: 8831770]
    HEK293 IC50
    0.1 μM
    Compound: Olanzapine
    Antagonist activity against 5-HT2A receptor (unknown origin) expressed in HEK293 cell membranes assessed as reduction in [35S]-GTPgammaS binding incubated for 30 mins by liquid scintillation counting method
    Antagonist activity against 5-HT2A receptor (unknown origin) expressed in HEK293 cell membranes assessed as reduction in [35S]-GTPgammaS binding incubated for 30 mins by liquid scintillation counting method
    		[PMID: 26227779]
    RAW264.7 CC50
    198.3 μM
    Compound: Olanzapine
    Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 38283231]
    WI-38 CC50
    > 100 μM
    Compound: Olanzapine
    Cytotoxicity against human WI38 cells assessed as reduction in cellular DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay
    Cytotoxicity against human WI38 cells assessed as reduction in cellular DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay
    		[PMID: 17893158]
    WI-38 EC50
    > 100 μM
    Compound: Olanzapine
    Antiviral activity against BKV Gardner ATCC VR837 infected in human WI38 cells assessed as reduction in viral DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay
    Antiviral activity against BKV Gardner ATCC VR837 infected in human WI38 cells assessed as reduction in viral DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay
    		[PMID: 17893158]
    In Vitro

    Olanzapine binds weakly to GABAA, Benzodiazepine (BZD), and β-adrenergic receptors (Ki>10 μM) [1][2].
    Olanzapine induces autophagy in human SH-SY5Y neuronal cell line[3].
    Olanzapine (1-100 μM for 144 h under serum starvation) results in a marked anti-proliferative effect in glioblastoma cell lines as well as glioma stem-like cells[4].
    Olanzapine also enhances Temozolomide (HY-17364)’s anti-tumor activity in glioblastoma cell lines[4].
    Olanzapine induces apoptosis and necrosis in glioblastoma cell lines[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Olanzapine Related Antibodies

    Cell Proliferation Assay[4]

    Cell Line: U87MG and A172 glioblastoma cell lines as well as SC38 and SC40 glioma stem-like cells
    Concentration: 1, 10, 100 μM
    Incubation Time: 144 h; under serum starvation (1.5 % FBS) prior to performing MTT-assays
    Result: Resulted in a marked antiproliferative effect with IC50 values ranging from 25 to 79.9 µM. In U87MG cells, anchorage-independent growth was dose-dependently inhibited. In A172 cells, migration was also shown to be inhibited in a dose-dependent manner.

    Western Blot Analysis[4]

    Cell Line: U87MG and A172 cells
    Concentration: 10, 25, 50, and 100 μM
    Incubation Time: 7 h, 24 h, 48 h, 72 h
    Result: Led to a dose responsive decrease of pAMPK expression after 72 h of treatment.
    In Vivo

    Olanzapine (0.75, 1.5 and 3 mg/kg) evaluates body weight and periuterine fat mass, as well as insulin, non-esterified fatty acids, triglycerides, and glucose levels in mice[5]

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Forty-two, 14, and 28 female CD-1 mice [5]
    Dosage: 0.75, 1.5 and 3 mg/kg
    Administration: Orally and chronically administered; 35 days
    Result: Increased body weight relative to vehicle on days 20-22, and from day 32 onwards there was a straightforward increase in body weight at 3 mg/kg. No differences were found between control and mice administered olanzapine at both 1.5 and 0.75 mg/kg.
    Clinical Trial
    Molecular Weight

    312.44

    Formula

    C17H20N4S
    CAS No.
    Appearance

    Solid

    Color

    Light yellow to yellow

    SMILES

    CC1=CC(C(N2CCN(C)CC2)=N3)=C(S1)NC4=C3C=CC=C4
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    4°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    Solvent & Solubility
    In Vitro: 

    DMSO : 20 mg/mL (64.01 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.2006 mL 16.0030 mL 32.0059 mL
    5 mM 0.6401 mL 3.2006 mL 6.4012 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2 mg/mL (6.40 mM); Clear solution

      This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2 mg/mL (6.40 mM); Clear solution

      This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.96%

    SDS (480 KB)

    COA (258 KB) HNMR (259 KB) RP-HPLC (255 KB) LCMS (95 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.2006 mL 16.0030 mL 32.0059 mL 80.0149 mL
    5 mM 0.6401 mL 3.2006 mL 6.4012 mL 16.0030 mL
    10 mM 0.3201 mL 1.6003 mL 3.2006 mL 8.0015 mL
    15 mM 0.2134 mL 1.0669 mL 2.1337 mL 5.3343 mL
    20 mM 0.1600 mL 0.8001 mL 1.6003 mL 4.0007 mL
    25 mM 0.1280 mL 0.6401 mL 1.2802 mL 3.2006 mL
    30 mM 0.1067 mL 0.5334 mL 1.0669 mL 2.6672 mL
    40 mM 0.0800 mL 0.4001 mL 0.8001 mL 2.0004 mL
    50 mM 0.0640 mL 0.3201 mL 0.6401 mL 1.6003 mL
    60 mM 0.0533 mL 0.2667 mL 0.5334 mL 1.3336 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Olanzapine Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Olanzapine132539-06-1LY170053LY 170053LY-1700535-HT ReceptorDopamine ReceptormAChRAdrenergic ReceptorAutophagyMitophagyApoptosisSerotonin Receptor5-hydroxytryptamine ReceptorMuscarinic acetylcholine receptorBeta ReceptorMitochondrial Autophagy5-HT2D1D2antipsychoticanticholinergicmitochondrialdamageSH-SY5YneuronalcellInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Olanzapine
    Cat. No.:
    HY-14541
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (480 KB) Français - FR (480 KB) Deutsch - DE (480 KB) Norwegian - NO (480 KB) Español - ES (480 KB) Swedish - SV (480 KB) Italian - IT (480 KB) Korean - KR (480 KB) Portuguese - PT (480 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.